Literature DB >> 30863587

Spread through air spaces in lung cancer patients is a risk factor for pulmonary metastasis after surgery.

Satoshi Shiono1, Makoto Endo1, Katsuyuki Suzuki1, Kazuki Hayasaka1, Naoki Yanagawa2.   

Abstract

BACKGROUND: Spread through air spaces (STAS) is regarded as a significant risk factor for lung cancer recurrence. STAS consists of micropapillary clusters, solid nests, or single cells beyond the edge of the tumor into air spaces in the surrounding lung parenchyma. However, the patterns of lung cancer recurrence have not been clarified in patients with STAS. The aim of this study was to explore STAS and recurrence patterns in patients who underwent lung cancer surgery.
METHODS: Between January 2000 and December 2017, a total of 1,426 patients underwent complete resection of lung cancer. We studied 848 patients with pathological stage I disease who underwent surgery. Recurrence patterns and recurrence-free rates were determined from pathological findings, particularly the presence of STAS. Locoregional recurrences included surgical margin recurrences, hilar and mediastinal lymph node metastases, ipsilateral lobe metastases, and pleural dissemination, whereas distant recurrences included extrathoracic organ and contralateral lobe metastases.
RESULTS: STAS was observed in 139 of 848 (16.4%) cases. Recurrences developed in 108 (12.7%) cases: locoregional recurrences in 76 (9.0%), distant metastases in 27 (3.2%), and both in 5 (0.6%) cases. Among recurrences, pleural dissemination developed in 12 (1.4%) and pulmonary metastases in 46 (5.4%) cases. Five-year recurrence-free rates were 65.4% among patients with STAS and 89.0% among patients without STAS. Univariate and multivariate analyses revealed that STAS was a significant risk factor for recurrence (P<0.001), particularly locoregional recurrence (P=0.005). In addition, STAS was a significant risk factor for pulmonary metastasis (P=0.009).
CONCLUSIONS: Among pathological stage I patients who undergo complete resection of lung cancer, patients with STAS tend to develop locoregional recurrence and pulmonary metastases.

Entities:  

Keywords:  Lung cancer; recurrence; spread through air spaces (STAS)

Year:  2019        PMID: 30863587      PMCID: PMC6384349          DOI: 10.21037/jtd.2018.12.21

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  29 in total

1.  Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade.

Authors:  Noriyoshi Sawabata; Etsuo Miyaoka; Hisao Asamura; Yoichi Nakanishi; Kenji Eguchi; Masaki Mori; Hiroaki Nomori; Yoshitaka Fujii; Meinoshin Okumura; Kohei Yokoi
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

2.  Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases.

Authors:  Romano Demicheli; Marco Fornili; Federico Ambrogi; Kristin Higgins; Jessamy A Boyd; Elia Biganzoli; Chris R Kelsey
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

3.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

4.  Winning the battle, losing the war: the noncurative "curative" resection for stage I adenocarcinoma of the lung.

Authors:  Sudish C Murthy; Scott I Reznik; Ugochukwu C Ogwudu; Carol F Farver; Andrea Arrossi; Lillian H Batizy; Edward R Nowicki; Tarek M Mekhail; David P Mason; Thomas W Rice; Eugene H Blackstone
Journal:  Ann Thorac Surg       Date:  2010-10       Impact factor: 4.330

5.  Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs.

Authors:  I Yoshino; T Yohena; M Kitajima; C Ushijima; K Nishioka; Y Ichinose; K Sugimachi
Journal:  Ann Thorac Cardiovasc Surg       Date:  2001-08       Impact factor: 1.520

6.  Tumor recurrence after complete resection for non-small cell lung cancer.

Authors:  Matthew D Taylor; Alykhan S Nagji; Castigliano M Bhamidipati; Nicholas Theodosakis; Benjamin D Kozower; Christine L Lau; David R Jones
Journal:  Ann Thorac Surg       Date:  2012-04-26       Impact factor: 4.330

7.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.

Authors:  Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03       Impact factor: 5.209

8.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

9.  Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.

Authors:  Maristela L Onozato; Alexandra E Kovach; Beow Y Yeap; Vicente Morales-Oyarvide; Veronica E Klepeis; Swathi Tammireddy; Rebecca S Heist; Eugene J Mark; Dora Dias-Santagata; A John Iafrate; Yukako Yagi; Mari Mino-Kenudson
Journal:  Am J Surg Pathol       Date:  2013-02       Impact factor: 6.394

10.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

View more
  5 in total

1.  Clinicopathological Impact of the Spread through Air Space in Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Jung-Soo Pyo; Nae Yu Kim
Journal:  Diagnostics (Basel)       Date:  2022-04-28

Review 2.  Current status and perspectives of spread through air spaces in lung cancer.

Authors:  Toshihiro Ikeda; Kyuichi Kadota; Tetsuhiko Go; Reiji Haba; Hiroyasu Yokomise
Journal:  Thorac Cancer       Date:  2021-05-05       Impact factor: 3.500

Review 3.  Significance of tumor spread through air spaces (STAS) in lung cancer from the pathologist perspective.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2020-06

4.  Impact of preoperative biopsy on tumor spread through air spaces in stage I non-small cell lung cancer: a propensity score-matched study.

Authors:  Yun Ding; Jiuzhen Li; Xin Li; Meilin Xu; Hua Geng; Daqiang Sun
Journal:  BMC Pulm Med       Date:  2022-07-30       Impact factor: 3.320

5.  Spread through air spaces (STAS) in invasive mucinous adenocarcinoma of the lung: Incidence, prognostic impact, and prediction based on clinicoradiologic factors.

Authors:  Min A Lee; Jun Kang; Ho Yun Lee; Wooil Kim; Insuk Shon; Na Young Hwang; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jae Ill Zo; Young Mog Shim
Journal:  Thorac Cancer       Date:  2020-09-25       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.